The performance of companies tied to Viagra's legacy presents a complex investment landscape. While the initial surge generated substantial returns , generic alternatives have significantly eroded market share . Investing in connected pharmaceutical companies now requires a careful assessment of patent rights , evolving patient shifts , and the pot